$AKTS News

Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37

Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate

JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33

Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40

Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Aktis Oncology: Mini-Proteins With A Targeted Punch

HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $35

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Aktis Oncology's AKY-2519 Shows Robust Tumor Uptake And Favorable Dosimetry Across Solid Tumors In First-In-Human B7-H3 Radiopharmaceutical Data Presented At ASCO 2026

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate

Aktis Oncology to Present at the BofA Securities Health Care Conference

Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Aktis Oncology Starts Phase 1b Clinical Study Of AKY-25191 In Participants With Metastatic Castration-resistant Prostate Cancer

William Blair Initiates Coverage On Aktis Oncology with Outperform Rating